SPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers
Friday, January 10, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses SPT-300, an innovative orally bioavailable prodrug of the neurosteroid allopregnanolone. It highlights the safety, tolerability, and clinical pharmacology of SPT-300 in healthy volunteers. This development could represent a significant advancement in neurosteroid therapies, offering new treatment avenues.
Market Sentiment Analysis
POSITIVE FACTORS
SPT-300 is a first-in-class orally bioavailable prodrug.
The study focuses on safety and tolerability in healthy volunteers.
Potential for significant advancements in neurosteroid therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - January 10, 2025
SPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers
Frequently Asked Questions
What is SPT-300?
SPT-300 is a first-in-class orally bioavailable prodrug of the neurosteroid allopregnanolone.
What was the focus of the SPT-300 study?
The study focused on the safety, tolerability, and clinical pharmacology of SPT-300 in healthy volunteers.
Why is SPT-300 significant?
SPT-300 represents a potential advancement in neurosteroid therapies, offering new treatment options.